Boehringer Ingelheim Pharma GmbH & Co. KG has synthesized NADPH oxidase 4 (NOX4) inhibitors reported to be useful for the treatment of atherosclerosis, cancer, pulmonary hypertension, inflammatory ...
The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, ...
The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, ...
A Phase 3 trial investigating Boehringer Ingelheim’s nerandomilast in idiopathic pulmonary fibrosis hit its primary endpoint, ...
GlobalData on MSN5d
Boehringer seeks approval for lung fibrosis drug following Phase III winThe Phase III trial evaluating nerandomilast as a treatment for idiopathic pulmonary fibrosis met its primary endpoint.
Topline data from FIBRONEER™-IPF show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in Forced Vital Capacity [mL] at week 52 ver ...
Boehringer Ingelheim announces plans to advance potential new treatment for Geographic Atrophy, following positive Phase I results GlobeNewswire September 05, 2024 Ingelheim, Germany and Basel ...
INGELHEIM, Germany, September 03, 2024 – Boehringer Ingelheim today said it has acquired Saiba Animal Health AG, a company focused on the development of novel therapeutic medicines to address ...
INGELHEIM, Germany, September 03, 2024 – Boehringer Ingelheim today said it has acquired Saiba Animal Health AG, a company focused on the development of novel therapeutic medicines to address chronic ...
Boehringer Ingelheim, a biopharmaceutical company involved in both human and animal health, has acquired Saiba Animal Health (SAH), a company that develops therapeutic vaccines, targeting unmet needs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback